Valbiotis
Biotechnology
Founded in 1/1/14
La Rochelle, Poitou-Charentes, France
For Profit
About Valbiotis
Valbiotis develops nutrition solutions to prevent cardio metabolic diseases and provides nutritional support for patients. The company develops Valedia, a product that is in Phase II clinical trials for the treatment of type 2 diabetes.
Company Metrics
- Employees: 11-50
- Monthly Visits: None
- Tech Stack: 62 active products
Financial Information
- Estimated Revenue: $10M to $50M
- Total Funding: 26500000 EUR
- Last Funding: 9700000 EUR (Post-IPO Equity)
- Funding Status: IPO
Technology Stack
Valbiotis actively uses 62 products in their tech stack.
Market Presence
Industries: Biotechnology
Headquarters: La Rochelle, Poitou-Charentes, France
Leadership
- Pascal Sirvent - Chief Scientific Officer (CSO), Director of Discovery, Preclinical and Translational Research LinkedIn
Employees
- Murielle Cazaubiel - Chief Medical, Regulatory & Industrial Affairs Officer (LinkedIn)
- Sebastien Bessy - Chief Operating Officer (LinkedIn)